Fulvestrant 500 mg or Anastrozole as First-Line Treatment in Advanced Breast Cancer


Fulvestrant 500 mg or Anastrozole as First-Line Treatment in Advanced Breast Cancer
Slides from a presentation at SABCS 2010 and transcribed comments from a recent interview with Harold J Burstein, MD, PhD (12/22/10)

Robertson JFR et al. A comparison of fulvestrant 500 mg with anastrozole as first-line treatment for advanced breast cancer: Follow-up analysis from the FIRST study. San Antonio Breast Cancer Symposium 2010;Abstract S1-3.

Dr Burstein is Associate Professor of Medicine at Harvard Medical School in Boston, Massachusetts.